and numerous other membrane remodeling processes. Moreover, dynamin is a promising target for therapeutic intervention in chronic kidney diseases (CKDs). We want to provide the basis for novel strategies

Matthias Jentschke Zeitschrift: Forum- Das offizielle Magazin der Deutschen Krebsgesellschaft e.V. A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical In

Helmholtz Center Munich 13.12.2023 REBIRTH Kolloquium (1 pm s.t., online Vortrag) ‘RNA-based therapeutic strategies for liver injuries’ Prof. Dr. Amar Deep Sharma, Department of Gastroenterology, Hepatology [...] Clinic of Pneumology and Infectiology, MHH ´Genetic skewing of macrophage function to enhance the therapeutic properties’ Schifaa Abdin (Group of Prof. Dr. Nico Lachmann), Department of Applied Stem Cell and [...] for Kidney and Hypertension Diseases, MHH ´Relevance of cardiovascular risk factors for novel therapeutic approaches´ Prof. Dr. Rabea Hinkel, German Primate Centre, Leibniz Institute for Primate Research

Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett 586 , 310-313. PubMed-Link Strotmeier J, Gu S, Jutzi S, Mahrhold

Engineering at the same institute. Professor Figueiredo is highly interested in cell and gene therapeutic approaches in the field of transfusion and transplantation. She has a long-term expertise in the

selected T-cells are addressing the burden of infection in patients often having no alternative therapeutic option available. Transplant Engineering This area of research focuses on the genetic engineering

Tsiavaliaris. Small molecule effectors of myosin motor proteins: novel pharmacological agents with therapeutic potential. Nov. 2018, Organisch-Chemisches Kolloquium der TU Dresden , Prof. Hans-Joachim Knölker

gene expression of Chlamydia trachomatis during persistent infection. A study to establish new therapeutic pathways and a better understanding of the pathogenesis of reactive arthritis Final exam November

Nidhi Jyotsana INDIA supervisor: Dr. Heuser, Haematology and Oncology, OE 6860, project: MN1 as a therapeutic target in AML Final exam June 2015 Piyushkumar Kapopara INDIA supervisor: Dr. Bavendiek, Cardiology

exam June 2013 Shashi Kumar Gupta INDIA supervisor: Prof. Dr. Thum, IFB-Tx, project: MicroRNAs as therapeutic targets in cardiac disease Final exam June 2013 Christine Happle (Dr.med.) GERMANY supervisor: